Drug Database · Clinicians

Vancomycin

Brands (90) Aekovan, Blincocin, Labvacom…Show all

US brand (reference label): Vancomycin Hydrochloride; not a Philippine-registered brand.

Antibacterial (glycopeptide antibacterial); Antibacterial (glycopeptide antibiotic); and others PH FDA category

Rx · Prescription drug123 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c757e65b-ca6f-4c00-afe2-025962b43d31, version date July 31, 2026 (Vancomycin Hydrochloride · Avenacy, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Vancomycin Hydrochloride for Injection administered intravenously is indicated for the treatment of: Septicemia
  • Infective Endocarditis
  • Skin and Skin Structure Infections
  • Bone Infections
  • Lower Respiratory Tract Infections
  • Clostridioides difficile -associated diarrhea
  • Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains)
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Vancomycin Hydrochloride for Injection is a glycopeptide antibacterial indicated in adult and pediatric patients less than 18 years of age as follows: Vancomycin Hydrochloride for Injection administered intravenously is indicated for the treatment of: Septicemia (1.1) Infective Endocarditis (1.2) Skin and Skin Structure Infections (1.3) Bone Infections (1.4) Lower Respiratory Tract Infections (1.5) Vancomycin Hydrochloride for Injection administered orally is indicated for the treatment of: Clostridioides difficile -associated diarrhea (1.6) Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) (1.7) Limitations of Use (1.8) Vancomycin Hydrochloride for Injection administered intravenously is not approved for the treatment of C. difficile -associated diarrhea and enterocolitis caused by susceptible isolates of Staphylococcus aureus because it is not effective. Vancomycin Hydrochloride for Injection administered orally is not approved for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections because it is not effective.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Injection and other antibacterial drugs, Vancomycin Hydrochloride for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.9) 1.1 Septicemia Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of septicemia due to: Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci.

Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.2 Infective Endocarditis Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of infective endocarditis due to: Susceptible isolates of MRSA. Viridans group streptococci Streptococcus gallolyticus (previously known as Streptococcus bovis), Enterococcus species and Corynebacterium species.

For enterococcal endocarditis, use Vancomycin Hydrochloride for Injection in combination with an aminoglycoside. Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis in combination with rifampin and an aminoglycoside. 1.3 Skin and Skin Structure Infections Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of skin and skin structure infections due to: Susceptible isolates of MRSA and coagulase negative staphylococci.

Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.4 Bone Infections Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of bone infections due to: Susceptible isolates of MRSA and coagulase negative staphylococci. Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.5 Lower Respiratory Tract Infections Vancomycin Hydrochloride for Injection administered intravenously is indicated in adults and pediatric patients less than 18 years of age for the treatment of lower respiratory tract infections due to: Susceptible isolates of MRSA Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.6 Clostridioides difficile -Associated Diarrhea Vancomycin Hydrochloride for Injection administered orally is indicated for the treatment of C. difficile -associated diarrhea (CDAD) in adult and pediatric patients less than 18 years of age. 1.7 Enterocolitis Caused by S. aureus (including methicillin-resistant strains) Vancomycin Hydrochloride for Injection administered orally is indicated for the treatment of enterocolitis caused by susceptible isolates of Staphylococcus aureus in adults and pediatric patients less than 18 years of age. 1.8 Limitations of Use Vancomycin Hydrochloride for Injection administered intravenously is not approved for the treatment of the following conditions because it is not effective: C. difficile -Associated Diarrhea Enterocolitis caused by susceptible isolates of Staphylococcus aureus Vancomycin Hydrochloride for Injection administered orally is not approved for the treatment of the following conditions because it is not effective: Septicemia due to susceptible isolates of MRSA or methicillin-susceptible staphylococci Infective endocarditis due to susceptible isolates of MRSA, methicillin susceptible staphylococci, Viridans group streptococci Streptococcus gallolyticus, Enterococcus species and Corynebacterium species, or for the treatment of early-onset prosthetic valve endocarditis caused by Staphylococcus epidermidis in combination with rifampin and an aminoglycoside Skin and skin structure infections due to susceptible isolates of MRSA and methicillin susceptible staphylococci Bone infections due to susceptible isolates of MRSA and lower respiratory tract infections due to susceptible isolates of MRSA and methicillin susceptible staphylococci 1.9 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Injection and other antibacterial drugs, Vancomycin Hydrochloride for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Known hypersensitivity to vancomycin
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Vancomycin Hydrochloride for Injection is contraindicated in patients with known hypersensitivity to vancomycin and polysorbate 80. Hypersensitivity to vancomycin, and polysorbate 80 (4)

Dosing: Adult

  • Serious infections (adults, normal kidney function): 15–20 mg/kg (actual body weight) IV every 8–12 hours, AUC-guided (target 400–600 mg·h/L); loading 20–35 mg/kg (maximum 3 g) if critically ill (Rybak 2020). Label alternative: 2 g/day (500 mg every 6 hours or 1 g every 12 hours), infused over at least 60 minutes
  • C. difficile-associated diarrhea (vial contents given orally; this label): 125 mg orally 4 times daily for 10 days
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • See full prescribing information for important information on intravenous and oral administration, preparation and storage instructions (2.1, 2.5, 2.8). Recommended Dosage and Administration Intravenous Use: Administer Vancomycin Hydrochloride for Injection in a diluted solution by intravenous infusion over 60 minutes or greater to reduce the risk of infusion reactions. Adult Patients: 2 grams (g) divided either as 0.5 g every 6 hours or 1 g every 12 hours (2.2)
  • Pediatric Patients (1 month and older): 10 mg/kg per dose given every 6 hours (2.2)
  • Pediatric Patients (younger than 1 month of age): See full prescribing information for recommended dosage (2.2)
  • Patients with Renal Impairment: See full prescribing information for recommended dosage in patients with renal impairment (2.4)
  • Oral use: Adult Patients (18 years of age or greater): C. difficile -Associated Diarrhea: 125 mg administered orally 4 times daily for 10 days (2.3). Staphylococcal enterocolitis: 500 mg to 2 grams administered orally in 3 or 4 divided doses for 7 to 10 days (2.3)
  • Pediatric Patients (less than 18 years of age): For both C. difficile -associated diarrhea and staphylococcal enterocolitis: 40 mg/kg in 3 or 4 divided doses for 7 days to 10 days. The total daily dosage should not exceed 2 g (2.3)
2.1 Important Administration Instructions for Intravenous Use

2.1 Important Administration Instructions for Intravenous Use To reduce the risk of infusion related adverse reactions, administer diluted Vancomycin Hydrochloride for Injection by intravenous infusion over 60 minutes or greater [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)]. Diluted Vancomycin Hydrochloride for Injection concentrations of no more than 5 mg/mL are recommended in adults [see Dosage and Administration (2.2)].

See also age-specific recommendations [see Dosage and Administration (2.2, 2.3)]. In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used. Infusion related events may occur, however, at any rate or concentration [see Warnings and Precautions (5.5)]. Other drugs should not be added to the diluted Vancomycin Hydrochloride for Injection [see Dosage and Administration (2.7)].

Administer diluted Vancomycin Hydrochloride for Injection prior to intravenous anesthetic agents to reduce the risk of infusion related adverse reactions [see Warnings and Precautions (5.5)]. Administer diluted Vancomycin Hydrochloride for Injection by a secure intravenous route of administration to avoid local irritation and phlebitis reactions [see Warnings and Precautions (5.6)].

2.2 Intravenous Dosage in Adult and Pediatric Patients with Normal Renal Function

2.2 Intravenous Dosage in Adult and Pediatric Patients with Normal Renal Function Dosage in Adult Patients The usual daily intravenous dose is 2 grams (g) divided either as 500 mg every 6 hours or 1 g every 12 hours. Administer each dose by intravenous infusion over a period of 60 minutes or greater. Other patient factors, such as age or obesity, may call for modification of the usual intravenous daily dose.

Dosage in Pediatric Patients Aged 1 Month and Older The usual intravenous dosage of vancomycin is 10 mg/kg per dose given every 6 hours. Each dose should be administered over a period of at least 60 minutes. Close monitoring of serum concentrations of vancomycin may be warranted in these patients. Dosage in Pediatric Patients Younger than 1 Month of Age In pediatric patients, up to the age of 1 month, the total daily intravenous dosage may be lower.

In neonates, an initial dose of 15 mg/kg is suggested, followed by 10 mg/kg every 12 hours for pediatric patients in the 1 st week of life and every 8 hours thereafter up to the age of 1 month. Each dose should be administered over 60 minutes. In premature infants, vancomycin clearance decreases as postconceptional age decreases.

Therefore, longer dosing intervals may be necessary in premature infants. Close monitoring of serum concentrations of vancomycin is recommended in these patients.

2.3 Orally Administered Dosage in Adult and Pediatric Patients

2.3 Orally Administered Dosage in Adult and Pediatric Patients Dosage in Adult Patients C. difficile -associated diarrhea: The recommended dose is 125 mg administered orally 4 times daily for 10 days. Staphylococcal enterocolitis: Total daily dosage is 500 mg to 2 g administered orally in 3 or 4 divided doses for 7 days to 10 days.

Dosage in Pediatric Patients (Less than 18 years of age) For both C. difficile -associated diarrhea and staphylococcal enterocolitis, the usual daily dosage is 40 mg/kg in 3 or 4 divided doses for 7 days to 10 days. The total daily dosage should not exceed 2 g.

2.4 Intravenous Dosage in Patients with Renal Impairment

2.4 Intravenous Dosage in Patients with Renal Impairment Dosage adjustment must be made in adult and pediatric patients with renal impairment. The initial dose should be no less than 15 mg/kg, in adult patients with any degree of renal impairment. In premature infants and the elderly, greater dosage reductions than expected may be necessary because of decreased renal function.

Measure trough vancomycin serum concentrations to guide therapy, especially in seriously ill patients with changing renal function. For functionally anephric patients, an initial dose of 15 mg/kg of body weight should be given to achieve prompt therapeutic serum concentration. A dose of 1.9 mg/kg/24 hr should be given after the initial dose of 15 mg/kg.

2.5 Directions for the Preparation, Dilution, and Storage of the Single-Dose Vials for…

2.5 Directions for the Preparation, Dilution, and Storage of the Single-Dose Vials for Intravenous Use Preparation Vancomycin Hydrochloride for Injection must be reconstituted and further diluted. No preservative is present in this product. Aseptic technique must be used in the preparation of final IV solution. Reconstitution of the Spray-dried Powder: At the time of use, reconstitute the vials of Vancomycin Hydrochloride for Injection with Sterile Water for Injection to a concentration of 50 mg of vancomycin/mL (see following table for volume of diluent).

Vancomycin Strength per Vial Volume of Diluent 500 mg 10 mL 750 mg 15 mL 1 gram 20 mL 1.25 grams 25 mL 1.5 grams 30 mL After reconstitution, the vials may be stored at 2°C to 8°C (36°F to 46°F) for 96 hours without significant loss of potency. Dilution Reconstituted solutions of vancomycin (50 mg/mL) must be further diluted.

A dose of 500 mg (10 mL) must be diluted with at least 100 mL of a suitable infusion solution. For doses of 750 mg (15 mL), at least 150 mL of solution must be used. For doses of 1 gram (20 mL), at least 200 mL of solution must be used. For doses of 1.25 grams (25 mL), at least 250 mL of solution must be used. For doses of 1.5 grams (30 mL), at least 300 mL of solution must be used.

The desired dose diluted in this manner should be administered by intermittent IV infusion over a period of at least 60 minutes. Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.

2.6 Compatibility with Intravenous Fluids

2.6 Compatibility with Intravenous Fluids for Intravenous Use The following diluents are physically and chemically compatible with approximately 4.5 mg/mL of vancomycin hydrochloride: 5% Dextrose Injection, USP 5% Dextrose Injection and 0.9% Sodium Chloride Injection, USP Lactated Ringer's Injection, USP 5% Dextrose and Lactated Ringer's Injection, USP 0.9% Sodium Chloride Injection, USP

2.7 Incompatibilities for Intravenous Use

2.7 Incompatibilities for Intravenous Use Vancomycin Hydrochloride for Injection reconstituted solution has a low pH and may cause chemical or physical instability when it is mixed with other compounds. Mixtures of solutions of vancomycin and beta-lactam antibacterial drugs have been shown to be physically incompatible.

The likelihood of precipitation increases with higher concentrations of vancomycin. It is recommended to adequately flush the intravenous lines between the administration of these antibacterial drugs. It is also recommended to dilute solutions of vancomycin to 5 mg/mL or less.

2.8 Preparation of Vancomycin Hydrochloride for Injection for Oral Administration

2.8 Preparation of Vancomycin Hydrochloride for Injection for Oral Administration Preparation of the Single-Dose Vial for Oral Use Reconstitute Vancomycin Hydrochloride for Injection to 100 mg/mL by adding the appropriate amount of sterile water for injection: Table 1: Reconstitution-Volume of Sterile Water for Injection to be Added Vancomycin Hydrochloride for Injection Strength per Vial Volume of Sterile Water for Injection to be added to achieve 100 mg/mL Vancomycin Hydrochloride Solution 500 mg 5 mL 750 mg 7.5 mL 1 gram 10 mL 1.25 grams 12.5 mL 1.5 grams 15 mL Sweeteners may be added to the solution to improve the taste for oral administration following the steps outlined in Instructions for How to Prepare and Add Sweeteners below. Instructions for How to Prepare and Add Sweeteners Prepare the sweetening agent separately from the reconstituted Vancomycin hydrochloride solution in a plastic container following one of the preparation options below: Mix sucrose and sterile water for injection in a 1:2 ratio (e.g., 10 g sucrose and 20 mL sterile water for injection) OR Mix agave nectar with an equal volume of sterile water for injection Mix the sweetening agent with the reconstituted Vancomycin hydrochloride solution in a 3:1 ratio (e.g., 30 mL sweetening agent with 10 mL vancomycin solution) to obtain a sweetened solution containing 25 mg/mL of vancomycin that is suitable for oral administration.

The diluted solution may be administered orally or via a nasogastric tube [see Dosage and Administration (2.3)].

2.9 Storage of Reconstituted and Diluted

2.9 Storage of Reconstituted and Diluted Vancomycin Hydrochloride for Injection for Intravenous or Oral Administration Intravenous Administration: Administer the compounded mixtures within 4 hours after preparation when storing at room temperature and 6 days when stored refrigerated (14 days for solutions made with 0.9% sodium chloride and 5% dextrose). Oral Administration: Store the diluted solution for oral use in a plastic container refrigerated at 2 o C to 8 o C (36°F to 46°F) for up to 10 days.

Dosing: Altered kidney function

Intravenous vancomycin needs kidney-based dose adjustment guided by serum concentrations. The US label sets an initial dose of no less than 15 mg/kg at any level of kidney function, then dosing by measured levels. The 2020 consensus guideline recommends weight-based loading that is not reduced for kidney function and area-under-the-curve (AUC) guided maintenance (target 400 to 600 mg·h/L).

Kidney function measure: Label gives no fixed eGFR or CrCl bands; dosing is concentration-guided.

Show full dosing details
eGFR ≥60
15–20 mg/kg (actual body weight) every 8–12 hours; AUC-guided (target 400–600 mg·h/L) (Rybak 2020). Label alternative: 2 g/day (0.5 g every 6 hours or 1 g every 12 hours), adjusted to serum concentrations.
eGFR 30–59
Loading dose is not reduced for kidney function: 20–35 mg/kg actual body weight (maximum 3 g) if critically ill (Rybak 2020). Then extend the interval and adjust maintenance by AUC or serum concentrations (label: initial dose no less than 15 mg/kg).
eGFR 15–29
Loading dose is not reduced for kidney function: 20–35 mg/kg actual body weight (maximum 3 g) if critically ill (Rybak 2020). Maintenance by AUC or serum concentrations (label: initial dose no less than 15 mg/kg).
eGFR <15 (not on dialysis)
Loading dose is not reduced for kidney function: 20–35 mg/kg actual body weight (maximum 3 g) if critically ill (Rybak 2020). Functionally anephric (label): 15 mg/kg initially, then about 1.9 mg/kg every 24 hours; guide further doses by serum concentrations.
Hemodialysis (intermittent)
Rybak 2020 (Rec 13; mg/kg, maintenance three times weekly): dose given after HD ends: load 25 mg/kg, then 7.5 mg/kg (low-permeability dialyzer) or 10 mg/kg (high-permeability). Dose given during HD (intradialytic): load 30 mg/kg (low-permeability) or 35 mg/kg (high-permeability), then 7.5–10 mg/kg (low) or 10–15 mg/kg (high). Loading by actual body weight, maximum 3,000 mg (Rec 11). Adjust to pre-dialysis concentrations: 15–20 mg/L is likely to give AUC 400–600 mg·h/L; check at least weekly (Rec 14). AUC-guided monitoring (Rybak 2020): target AUC 400–600 mg·h/L (MIC 1 mg/L) for serious MRSA infection; on intermittent hemodialysis use pre-dialysis levels, timed per the pharmacy/laboratory AUC protocol. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
Peritoneal dialysis
For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 15–30 mg/kg every 5 to 7 days (CAPD) or 15 mg/kg every 4 days (APD); continuous loading dose 20–25 mg/kg, then 25 mg/L in each exchange. Supplemental doses may be needed in APD; redose guided by serum levels. Vancomycin enters peritoneal dialysis fluid (label). Specialist input.
CRRT
Load 20–25 mg/kg actual body weight, then 7.5–10 mg/kg every 12 hours at effluent 20–25 mL/kg/h; guide maintenance by serum concentrations within the first 24 hours (Rybak 2020, Rec 16).
PIRRT / SLED
Hybrid HD (PIRRT/SLED): load 20–25 mg/kg actual body weight; do not delay the first dose until the session ends; then 15 mg/kg after each session or during its final 60–90 minutes (Rybak 2020, Rec 15).
  • Dialyzable? Yes with high-flux HD (substantial removal each session; the label's 'poorly removed' statement reflects older low-flux membranes). Give maintenance doses after HD or during the last part of the session.
  • Monitoring Serum concentrations (AUC-guided, target 400–600 mg·h/L, per consensus; trough per label); pre-dialysis levels at least weekly on hemodialysis; serum creatinine; nephrotoxicity risk rises with other nephrotoxins.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
≥3 months, serious MRSA: 60–80 mg/kg/day divided every 6–8 hours, AUC-guided (Rybak 2020). Label: 10 mg/kg every 6 hours.
eGFR 30–59
Reduce the dose for kidney impairment and guide by AUC (preferably Bayesian) or serum concentrations (Rybak 2020, Rec 19–20). Label: initial dose no less than 15 mg/kg, then by levels.
eGFR 15–29
Reduce the dose for kidney impairment and guide by AUC (preferably Bayesian) or serum concentrations (Rybak 2020, Rec 19–20). Label: initial dose no less than 15 mg/kg, then by levels.
eGFR <15 (not on dialysis)
Reduce the dose for kidney impairment and guide by AUC (preferably Bayesian) or serum concentrations (Rybak 2020, Rec 19–20). Label: initial dose no less than 15 mg/kg, then by levels.
Hemodialysis (intermittent)
No pediatric dialysis or CRRT recommendation in the label or Rybak 2020; dose by levels with specialist (pediatric nephrology/infectious diseases) input.
Peritoneal dialysis
No pediatric dialysis or CRRT recommendation in the label or Rybak 2020; dose by levels with specialist (pediatric nephrology/infectious diseases) input.
CRRT
No pediatric dialysis or CRRT recommendation in the label or Rybak 2020; dose by levels with specialist (pediatric nephrology/infectious diseases) input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.4 Intravenous Dosage in Patients with Renal Impairment Dosage adjustment must be made in adult and pediatric patients with renal impairment. The initial dose should be no less than 15 mg/kg, in adult patients with any degree of renal impairment. In premature infants and the elderly, greater dosage reductions than expected may be necessary because of decreased renal function.

Measure trough vancomycin serum concentrations to guide therapy, especially in seriously ill patients with changing renal function. For functionally anephric patients, an initial dose of 15 mg/kg of body weight should be given to achieve prompt therapeutic serum concentration. A dose of 1.9 mg/kg/24 hr should be given after the initial dose of 15 mg/kg.

8.6 Renal Impairment Dosage adjustment must be made in patients with impaired renal function [see Dosage and Administration (2.3)]. Measure trough vancomycin serum concentrations to guide intravenous therapy, especially in seriously ill patients with changing renal function.

Dosing: Pediatric

Approved ages
IV: pediatric patients under 18 years for the labeled infections (label 1.1–1.5, 8.4).
Usual dose
3 months and older, normal kidney function, serious MRSA: 60–80 mg/kg/day divided every 6–8 hours, AUC-guided (Rybak 2020, Rec 17). Label: 10 mg/kg every 6 hours (1 month and older).
Maximum dose
Usually 3,600 mg/day empirically; most children should not need more than 3,000 mg/day; check levels early when doses exceed 2,000–3,000 mg/day (Rybak 2020, Rec 18).
Neonates
Neonates (label): initial 15 mg/kg, then 10 mg/kg every 12 hours in the first week of life and every 8 hours thereafter up to 1 month of age.

Target AUC 400 mg·h/L, potentially up to 600, in children; keep AUC below 800 and trough below 15 mg/L to limit acute kidney injury; avoid 100 mg/kg/day or more (Rec 21). Monitoring may begin within 24–48 hours (Rec 20). Nonobese children: insufficient data for a loading dose (Rec 22). Obese children: loading 20 mg/kg total body weight (Rec 24). Neonates and infants up to 3 months: 10–20 mg/kg every 8–48 hours by postmenstrual age, weight and serum creatinine (Rec 25).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use Vancomycin Hydrochloride for Injection administered intravenously is indicated in pediatric patients less than 18 years of age for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections [see Indications and Usage (1.1 to 1.5) and Dosage and Administration (2.2)]. Vancomycin Hydrochloride for Injection administered orally is indicated in pediatric patients less than 18 years of age for the treatment of Clostridioides difficile -associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) [see Indications and Usage (1.6, 1.7) and Dosage and Administration (2.3)].

In pediatric patients, monitor vancomycin serum concentration and renal function when administering Vancomycin Hydrochloride for Injection intravenously [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)]. More severe infusion related reactions related to Vancomycin Hydrochloride for Injection administration may occur in pediatric patients.

Concomitant administration of vancomycin and intravenous anesthetic agents has been associated with erythema and histamine-like flushing in all patients including pediatric patients [see Warnings and Precautions (5.5)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies with another vancomycin hydrochloride drug product in C. difficile -associated diarrhea have demonstrated that geriatric subjects are at increased risk of developing nephrotoxicity following treatment with oral vancomycin hydrochloride, which may occur during or after completion of therapy. In patients over 65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with Vancomycin Hydrochloride for Injection to detect potential vancomycin induced nephrotoxicity [see Warnings and Precautions (5.1)] and Adverse Reactions (6.1)].

Patients over 65 years of age may take longer to respond to therapy compared to patients 65 years of age and younger. Clinicians should be aware of the importance of appropriate duration of Vancomycin Hydrochloride for Injection treatment in patients over 65 years of age and not discontinue or switch to alternative treatment prematurely.

Vancomycin Hydrochloride for Injection is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection [see Dosage and Administration (2.4)], and it may be useful to monitor renal function [see Warnings and Precautions (5.1)].

Administration

2.1 Important Administration Instructions for Intravenous Use To reduce the risk of infusion related adverse reactions, administer diluted Vancomycin Hydrochloride for Injection by intravenous infusion over 60 minutes or greater [see Warnings and Precautions ( 5.5 ) and Adverse Reactions ( 6.1 )] . Diluted Vancomycin Hydrochloride for Injection concentrations of no more than 5 mg/mL are recommended in adults [see Dosage and Administration ( 2.2 )]. See also age-specific recommendations [see Dosage and Administration ( 2.2 , 2.3 )] . In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used. Infusion related events may occur, however, at any rate or concentration [see Warnings and Precautions ( 5.5 )]. Other drugs should not be added to the diluted Vancomycin Hydrochloride for Injection [see Dosage and Administration ( 2.7 )] . Administer diluted Vancomycin Hydrochloride for Injection prior to intravenous anesthetic agents to reduce the risk of infusion related adverse reactions [see Warnings and Precautions ( 5.5 )]. Administer diluted Vancomycin Hydrochloride for Injection by a secure intravenous route of administration to avoid local irritation and phlebitis reactions [see Warnings and Precautions ( 5.6 )] .

2.5 Directions for the Preparation, Dilution, and Storage of the Single-Dose Vials for Intravenous Use Preparation Vancomycin Hydrochloride for Injection must be reconstituted and further diluted . No preservative is present in this product. Aseptic technique must be used in the preparation of final IV solution. Reconstitution of the Spray-dried Powder : At the time of use, reconstitute the vials of Vancomycin Hydrochloride for Injection with Sterile Water for Injection to a concentration of 50 mg of vancomycin/mL (see following table for volume of diluent). Vancomycin Strength per Vial Volume of Diluent 500 mg 10 mL 750 mg 15 mL 1 gram 20 mL 1.25 grams 25 mL 1.5 grams 30 mL After reconstitution, the vials may be stored at 2°C to 8°C (36°F to 46°F) for 96 hours without significant loss of potency. Dilution Reconstituted solutions of vancomycin (50 mg/mL) must be further diluted. A dose of 500 mg (10 mL) must be diluted with at least 100 mL of a suitable infusion solution. For doses of 750 mg (15 mL), at least 150 mL of solution must be used. For doses of 1 gram (20 mL), at least 200 mL of solution must be used. For doses of 1.25 grams (25 mL), at least 250 mL of solution must be used. For doses of 1.5 grams (30 mL), at least 300 mL of solution must be used. The desired dose diluted in this manner should be administered by intermittent IV infusion over a period of at least 60 minutes. Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.

2.6 Compatibility with Intravenous Fluids for Intravenous Use The following diluents are physically and chemically compatible with approximately 4.5 mg/mL of vancomycin hydrochloride: 5% Dextrose Injection, USP 5% Dextrose Injection and 0.9% Sodium Chloride Injection, USP Lactated Ringer's Injection, USP 5% Dextrose and Lactated Ringer's Injection, USP 0.9% Sodium Chloride Injection, USP

2.7 Incompatibilities for Intravenous Use Vancomycin Hydrochloride for Injection reconstituted solution has a low pH and may cause chemical or physical instability when it is mixed with other compounds. Mixtures of solutions of vancomycin and beta-lactam antibacterial drugs have been shown to be physically incompatible. The likelihood of precipitation increases with higher concentrations of vancomycin. It is recommended to adequately flush the intravenous lines between the administration of these antibacterial drugs. It is also recommended to dilute solutions of vancomycin to 5 mg/mL or less.

2.8 Preparation of Vancomycin Hydrochloride for Injection for Oral Administration Preparation of the Single-Dose Vial for Oral Use Reconstitute Vancomycin Hydrochloride for Injection to 100 mg/mL by adding the appropriate amount of sterile water for injection: Table 1: Reconstitution-Volume of Sterile Water for Injection to be Added Vancomycin Hydrochloride for Injection Strength per Vial Volume of Sterile Water for Injection to be added to achieve 100 mg/mL Vancomycin Hydrochloride Solution 500 mg 5 mL 750 mg 7.5 mL 1 gram 10 mL 1.25 grams 12.5 mL 1.5 grams 15 mL Sweeteners may be added to the solution to improve the taste for oral administration following the steps outlined in Instructions for How to Prepare and Add Sweeteners below. Instructions for How to Prepare and Add Sweeteners Prepare the sweetening agent separately from the reconstituted Vancomycin hydrochloride solution in a plastic container following one of the preparation options below: Mix sucrose and sterile water for injection in a 1:2 ratio (e.g., 10 g sucrose and 20 mL sterile water for injection) OR Mix agave nectar with an equal volume of sterile water for injection Mix the sweetening agent with the reconstituted Vancomycin hydrochloride solution in a 3:1 ratio (e.g., 30 mL sweetening agent with 10 mL vancomycin solution) to obtain a sweetened solution containing 25 mg/mL of vancomycin that is suitable for oral administration. The diluted solution may be administered orally or via a nasogastric tube [see Dosage and Administration ( 2.3 )] .

US FDA label

Dosage forms

Philippines

  • Powder for injection: 1 g, 500 mg
  • Lyophilized powder for injection: 1 g, 500 mg
  • Lyophilized powder for iv infusion: 1 g, 500 mg
  • Powder for solution for iv infusion: 1 G, 500 mg
  • Powder for iv infusion: 1 g, 500 mg
  • Dry powder for injection: 1 g
  • Lyophilized powder for injection for i.v. infusion: 1 g
  • Powder for i.v. infusion: 1 g
  • Powder for solution for infusion: 1 g, 500 mg
  • ) powder for iv infusion: 500 mg (500,000 IU

and 9 more forms; see the products table.

Registered products in the Philippines

123 products registered with the Food and Drug Administration (FDA) Philippines list Vancomycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products123
Philippine FDA-registered products for Vancomycin
Package insert
AekovanVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL Capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Dynasty PharmaceuticalsImporter: Ambica International Corporation
DRP-7387-06
Oct 4, 2027
AekovanVancomycin hydrochloride
500 mg Powder for Infusion (IV)USP Type I Glass Vial with Yellow Flip-off Seal x 10 mL (Box of 1's)
Rx
Korea Unite Pharm. Inc.Republic of Korea
DYNASTY PHARMACEUTICALS
DRP-6421
Aug 9, 2028
AekovanVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Dynasty PharmaceuticalsImporter: Ambica International Corporation
DRP-7386-08
Oct 4, 2027
Avancomycin 1Vancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Marcburg Philippines Inc.Importer: Ambica International Corporation
DRP-7387-03
Oct 4, 2027
Avancomycin 500Vancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
BioRx Pharma Labs LLPIndia
Marcburg Philippines Inc.Importer: Ambica International Corporation
DRP-7386-03
Oct 4, 2027
BlincocinVancomycin (as hydrochloride)
1 g Powder for Injection (IV)20 mL-capacity Type I Clear glass vial with bromobutyl rubber stopper and blue aluminium flip-off seal (Box of 1's)
Rx
Venus Remedies LimitedIndia
Triple Tact Import & Export Corp.Importer: Afree Pharmaceutical Distribution Corp.
DRP-10631
Dec 9, 2026
BLINCOCINVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)10 mL-capacity Type I Clear glass vial with bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
Rx
Venus Remedies LimitedIndia
Afree Pharmaceutical Distribution Corp.Importer: Afree Pharmaceutical Disribution Corp.
DRP-10630
Nov 10, 2031
ClevanVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)USP Type I clear glass vial with blue plastic flip off cap (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Remker Drug, Inc.Importer: H & B Pharma International Inc.
DRP-5822-01
Aug 27, 2028
CovanVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (I.V.)USP Type I clear colorless glass vial with lyophilized rubber stopper and dark blue aluminum cap (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd. (1357)Republic of Korea
Ellebasy Medicale Group Inc.Importer: JLT Pharma Inc.
DRP-9845-01
Jul 15, 2031
Diacin 500Vancomycin (as hydrochloride)
500mg Powder for Solution for IV Infusion10 mL USP Type I Glass Vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7335-05
Sep 18, 2027
ImvacoVancomycin (as hydrochloride)
1 g Lyophilized Powder for Injection (IV Infusion)USP Type I Glass vial x 20 mL and 2 USP Type III flint glass ampoules (diluent) x 20 mL (Box of 1's)
Rx
GUFIC BIOSCIENCES INC.India
TRIPLE TACT IMPORT & EXPORT CORP.Importer: SRS LIFE SCIENCES INC.
DR-XY40975
Jun 21, 2027
JennycinVancomycin (as hydrochloride)
1 g Powder for IV Infusion20 mL-capacity USP Type III moulded glass vial with gray bromobutyl rubber stopper and blue flip-off seal x 1's + 2 Sterile Water for Injection (diluent) in USP Type I Clear glass ampoule x 10 mL in a box.
Rx
Shree Anand Life Sciences, Ltd.India
Best ClearImporter: Medinova Pharmaceutical Inc.
DRP-14780-02
Jan 4, 2029
LabvacomVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Labmate Pharma Inc.Importer: Ambica International Corporation
DRP-7387-09
Oct 4, 2027
LabvacomVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
BioRx Pharma Labs LLPIndia
Labmate Pharma Inc.Importer: Ambica International Corporation
DRP-7386-01
Oct 4, 2027
Mersa IV 1000Vancomycin (As Hydrochloride)
1g Lyophilized Powder For Injection (For IV Infusion)20 mL Vial (USP type 1 clear glass vial) with Lyophilized rubber stopper and aluminum cap (Box of l's)
Rx
BCWorld Pharma Co., Ltd.Korea
The Cathay Drug Co., Inc.Importer: Daewoong Pharma Philippines, Incorporated
DRP-7395
May 6, 2027
Mersa IV 500Vancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (for I.V. Infusion)USP Type 1 Clear Glass Vial (Box of 1's)
Rx
BCWorld Pharm Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.Importer: Daewoong Pharma Philippines, Incorporated
DRP-7396
Feb 23, 2031
MyreskibVancomycin (As Hydrochloride)
500 mg Lyophilized Powder for Injection (I.V.)10 mL Type I Glass Vial with Dark Grey Bromobutyl Rubber Closure and Aluminum Flip-Off Seal (Box of 1's)
Rx
Mylan Laboratories Limited [Specialty Formulation Facility]India
Mylan Philippines, Inc.
DRP-11907
May 19, 2027
Navcocyn 1000Vancomycin (as hydrochloride)
1 g Powder for IV Infusion20 mL-capacity USP Type III moulded glass vial with gray bromobutyl rubber stopper and blue flip-off seal x 1's + 2 Sterile Water for Injection (diluent) in USP Type I Clear glass ampoule x 10 mL in a box.
Rx
Shree Anand Life Sciences, Ltd.India
Jn Carlo Pharmaceuticals DistributorImporter: Medinova Pharmaceutical Inc.
DRP-14780-03
Jan 4, 2029
NAVCOCYN 500Vancomycin (as hydrochloride)
500 mg Powder for Injection (IV Infusion)Glass Vial with 20 mm Flip-Off Seal and 20 mm Grey Butyl Rubber Stopper x 10 mL (Box of 1's)
Rx
Swiss Parenterals Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: Medinova Pharmaceutical Inc.
DRP-15597-01
Aug 8, 2029
NoneVancomycin (as Hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-7387-08
Oct 4, 2027
NoneVancomycin Hydrochloride
1g Lyophilized Powder for Injection (IV Infusion)10mL-capacity USP Type I glass vial with grey chlorobutyl rubber stopper, aluminum seal and yellow flip-off cap (Box of 1's)
Rx
Hankook Korus Pharm. Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.Importer: Bestco. Pharma International Corporation
DRP-17037-01
Sep 12, 2030
NoneVancomycin Hydrochloride
500 mg (500,000 IU) Powder for IV InfusionClear Type I Glass Vial with green flip-off seal (Box of 1’s)
Rx
Hospira Australia Pty. Ltd.Australia
Importer: Pfizer, Inc.
DR-XY12581
Apr 6, 2029
NoneVancomycin Hydrochloride
500 mg Lyophilized Powder for Injection (IV Infusion)10mL-capacity USP Type I Glass Vial with Grey Chlorobutyl Rubber Stopper, Aluminum Seal and Green Flip-Off Cap (Box of 1’s)
Rx
Hankook Korus Pharm. Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.Importer: Bestco. Pharma International Corporation
DRP-17038-01
Sep 13, 2030
NoneVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (IV)USP Type I clear colorless glass vial with lyophilized rubber stopper and dark blue aluminum cap (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd.Republic of Korea
Ritemed Phils., Inc.Importer: JLT Pharma, Inc.
DRP-9845
Jul 15, 2031
NoneVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V.)USP Type I Borosilicate Glass Vial w/ rubber stopper and blue flip off seal Box of 10's
Rx
Yooyoung Pharmaceutical Co., Ltd.Republic of Korea
Endure Medical, Inc.
DR-XY33630
Jul 16, 2027
NycovanVancomycin hydrochloride
1 g Powder for Injection (IV Infusion)20 mL-capacity Type III clear glass vial with aluminum seal, gray butyl rubber stopper and purple flip-off cap (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
Applied Pharmaceutical Distribution, Inc.
DRP-14849
Jan 23, 2031
OrsaVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)Flint, USP Type III Glass Vial with grey butyl rubber plugs, aluminum seal and green flip-off cap x 10 mL (Box of 1's)
Rx
Ciron Drugs & Pharmaceuticals Pvt. Ltd.India
Biocare Lifesciences, Inc
DRP-6715
Jun 14, 2031
PhilvanVancomycin (as Hydrochloride)
1 g Lyophilized Powder for IV Infusion20 mL USP Type I Clear Moulded Glass Vial with Grey Rubber Stopper and Light Pink Flip-off Seal Packed in Individual Box (Box of 10's)
Rx
United Biotech Pvt. Ltd.India
Triple Tact Import & Export Corp.
DRP-12456
Aug 10, 2027
PhilvanVancomycin (as Hydrochloride)
500 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Moulded Glass Vial (Box of l's)
Rx
United Biotech Pvt. Ltd.India
Triple Tact Import & Export Corp.
DRP-11780
Jul 21, 2027
Pol-VancoVancomycin (as hydrochloride)
1 g Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear glass vial with clear flip-off cap and rubber stopper x 15 mL (Box of 1's)
Rx
Aroma İlaç Sanayi. Ltd. ŞTİ.Turkey
Endure Medical, Inc.Trader: N/A
DR-XY49244
Oct 8, 2029
Pol-VancoVancomycin (as hydrochloride)
500 mg Powder for Injection for I.V. InfusionUSP Type I clear glass vial with clear flip-off cap and rubber stopper x 15 mL (Box of 1's)
Rx
Aroma İlaç Sanayi. Ltd. ŞTİ.Turkey
Endure Medical, Inc.
DR-XY49245
Oct 8, 2029
ReyocinVancomycin (As Hydrochloride)
1 g Powder For Injection (IV)10-mL capacity USP Type II Tubular vial with aluminum flip-off cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmakon Biotec Inc.
DRP-11414
Mar 17, 2027
ReyocinVancomycin (As Hydrochloride)
500 mg Powder For Injection (IV)10-mL capacity USP Type II Tubular vial with aluminum flip-off cap (Box of l’s)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmakon Biotec Inc.
DRP-11415
Mar 17, 2027
StanmycinVancomycin (as hydrochloride)
1 g Powder for Injection (IV)10-mL capacity USP Type II Tubular Vial with Aluminum Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Altor Pharmaceutical Product DistributionImporter: Pharmakon Biotec Inc.
DRP-11414-01
Mar 17, 2027
StavanceVancomycin (as hydrochloride)
1 g Lyophilized Powder for IV Infusion30 mL-capacity USP Type I Vial with gray bromobutyl rubber stopper and gray aluminum flip-off seal (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-10550
Oct 20, 2031
StavanceVancomycin (as hydrochloride)
500 mg Lyophilized Powder for IV Infusion20 mL-capacity USP Type I Vial with gray bromobutyl rubber stopper and sky-blue aluminum flip-off seal (Box of 1's)
Rx
Aspiro Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-10541
Oct 20, 2031
UnasenzVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V.)USP Type I clear glass vial with blue plastic flip-off cap (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Central West Medicale Inc.Importer: H & B Pharma International Inc.
DRP-5822-02
Aug 27, 2028
UnbrandedVancomycin
1 g Powder for Injection (I.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's, 10's, and 50's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Reta DrugImporter: Ambicare Pharmaceuticals Inc.
DRP-11397-03
Mar 8, 2032
UnivanVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear Colorless Glass Vial with Lyophilized Rubber Stopper and Dark Blue Aluminum Cap (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd. (1357)Republic of Korea
H & B Pharma International Inc.Importer: JLT Pharma, Inc.
DRP-9845-03
Jul 15, 2031
UnivanVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)USP Type I clear glass vial with blue plastic off cap (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Uni-Pharma Phils., Inc.Importer: H & B Pharma International Inc.
DRP-5822
Aug 27, 2028
Univanq-1000Vancomycin hydrochloride
1 g Powder for Solution for Infusion (IV)Type I clear glass vial with chlorobutyl rubber-stopper and aluminum flip-off cap (box of 1's)
Rx
Able Medical Company LimitedThailand
Uni-Pharma Phils., Inc
DRP-17855
Mar 25, 2031
Univanq-500Vancomycin hydrochloride
500 mg Powder for Solution for Infusion (IV)Type I clear glass vial with chlorobutyl rubber-stopper and aluminum flip-off cap (box of 1's)
Rx
Able Medical Company LimitedThailand
Uni-Pharma Phils., Inc
DRP-17856
Mar 25, 2031
ValvancoVancomycin (as hydrochloride)
1 g Dry Powder for Injection (IV Infusion)20 mL Clear Glass Vial Sealed with Gray Butyl Rubber Stopper and Sky-Blue Flip-off Seal Cap x 1’s (Box of 1’s)
Rx
Skymap Pharmaceutical Private LimitedIndia
SwissPharmatech Co.Importer: AMB HK Enterprises Inc.
DRP-14583-01
Oct 18, 2028
VamicynVancomycin (as hydrochloride)
500 mg Powder for IV Infusion10 mL-Capacity USP Type II Clear Colorless Glass Tubular vial with Gray Butyl Rubber Stopper and Blue colored Aluminum-Plastic Cap (Box of 10's)
Rx
Furen Pharmaceutical Group Co., Ltd.China
Endure Medical, Inc.
DR-XY48428
Oct 18, 2027
VAN-CP 1 gmVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Ambica International Corporation
DRP-7387
Oct 4, 2027
VAN-CP 500Vancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block B)India
Ambica International Corporation
DRP-7386
Oct 4, 2027
VancinVancomycin (as hydrochloride)
500 mg Lyophilized Powder For IV Infusion10 mL USP Type I Glass Vial + 10 mL USP Type III Flint Glass Ampoule (Sterilized Water For Injection As Diluent) (Box of 1's)
Rx
GUFIC BIOSCIENCES LTD.India
ENDURE MEDICAL, INC.Importer: SRS LIFE SCIENCES INC.
DRP-9864-01
Jun 21, 2027
Vanclaz-1000Vancomycin (as hydrochloride)
1 g Powder for IV Infusion20 mL-capacity USP Type III moulded glass vial with gray bromobutyl rubber stopper and blue flip-off seal x 1's 2 Sterile Water for Injection (diluent) in USP Type I Clear glass ampoule x 10 mL in a box
Rx
Shree Anand Life Sciences, Ltd.India
Medinova Pharmaceutical Inc.
DRP-14780
Jan 4, 2029
VancobizaVancomycin (as hydrochloride)
1 g Powder For Injection (IV)20 mL-capacity Type I transparent glass vial with chlorobutyl stopper and aluminum flip-off and polypropylene cap (Box of l's and 10's)
Rx
Laboratorio Reig Jofre, SASpain
Penta Labs Australia (Philippines)
DRP-11287
Mar 7, 2027
VancobizaVancomycin (as hydrochloride)
500 mg Powder For Injection (IV)10 mL-capacity Type I transparent glass vial with chlorobutyl stopper and aluminum flip-off and polypropylene cap (Box of l's and 10's)
Rx
Laboratorio Reig Jofre, SASpain
Penta Labs Australia (Philippines)
DRP-11286
Mar 7, 2027
Vancoblis 1000Vancomycin (as hydrochloride)
1 G Powder for Solution for IV Infusion20mL USP Type I Glass vial Box of 1's
Rx
Alwin DMD PharmaceuticalsIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-7336
Sep 18, 2027
Vancoblis 500Vancomycin (as hydrochloride)
500mg Powder for Solution for IV Infusion10 mL USP Type I Glass Vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-7335
Sep 18, 2027
VancocentVancomycin (as Hydrochloride)
1 g Lyophilized Powder for I.V. Infusion20 mL USP Type I Clear Moulded Glass Vial with Grey Rubber Stopper and Light Pink Flip-off Seal Packed in Individual Box (Box of 10's)
Rx
United Biotech Pvt. Ltd.India
Central West Medicale Inc.Importer: Triple Tact Import & Export Corp.
DRP-12456-01
Aug 10, 2027
Vancocent 500Vancomycin (as Hydrochloride)
500 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Moulded Glass Vial (Box of 1 's)
Rx
United Biotech Pvt. Ltd.India
Central West Medicale Inc.Importer: Triple Tact Import & Export Corp.
DRP-11780-01
Jul 21, 2027
VancochelVancomycin (as hydrochloride)
1 G Powder for Solution for IV Infusion20 mL USP Type I Glass Vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
AFREE PHARMACEUTICAL DISTRIBUTION CORP.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7336-04
Sep 18, 2027
VancocyVancomycin (as hydrohloride)
500mg Powder for Solution for I.V. InfusionUSP Type I Glass vial x 10 mL Box of 1's
Rx
Alwin DMD PharmaceuticalsIndia
Cyden Medicale TradingImporter: Bliss Pharma Distribution and Consultancy Corp.
DRP-7335-01
Sep 18, 2027
VancocymVancomycin (as hydrochloride)
1 g Powder for Solution for IV Infusion20 mL USP Type I Glass Vial (Box of 1's)
Rx
Alwin DMD PhamraceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7336-05
Sep 18, 2027
Vancocym 500Vancomycin (as hydrochloride)
500mg Powder for Solution for IV Infusion10mL USP Type I Glass vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7335-06
Mar 18, 2027
VancocynVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)10 mL-capacity USP Type III glass vial with gray bromobutyl rubber stopper and bio-violet colored flip-off seal (Box of 1's)
Rx
Karnataka Antibiotics & Pharma Ltd.India
Jackson Pharmaceuticals Inc.Trader: Vida Laboratories (P) Limited
DR-XY47716
Mar 2, 2027
Vancofree 1000Vancomycin (as hydrochloride)
1 g Powder for Solution for IV Infusion20 mL USP Type 1 Glass Vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
TRIPLE TACT IMPORT & EXPORT CORP.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-7336-03
Sep 18, 2027
Vancofree 500Vancomycin (as hydrochloride)
500mg Powder for Solution for IV Infusion10 mL USP Type I Glass Vial (Box of 1's)
Rx
Alwin DMD PharmaceuticalsIndia
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP=7335-04
Sep 18, 2027
VancoGet 1000Vancomycin (as hydrochloride)
1 g Powder for Injection (I.V.)20 mL-net capacity USP Type III clear glass vial with grey bromo butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
2MG Incorporated
DRP-16233
Jan 3, 2030
VancoGet 500Vancomycin (as hydrochloride)
500 mg Powder for Injection (I.V.)10 mL-net capacity USP Type III clear glass vial with grey bromo butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block-B)India
2MG Incorporated
DRP-16234
Jan 3, 2030
VancojorVancomycin
1 g Powder for Injection (l.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's, 10's and 50's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Ambicare Pharmaceuticals Inc.
DRP-11397
Mar 8, 2032
VancojorVancomycin
500 mg Powder for Injection (I.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's, 10's and 50's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-11398
Mar 8, 2027
VancokemVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd..India
Alkem Laboratories CorporationImporter: Ambica International Corporation
DRP-7387-05
Oct 4, 2027
VancokemVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
BioRx Pharma Labs LLPIndia
Alkem Laboratories CorporationImporter: Ambica International Corporation
DRP-7386-07
Oct 4, 2027
VancolevVancomycin (as Hydrochloride)
1 g Lyophilized Powder for IV Infusion20 mL USP Type I Clear Moulded Glass Vial with Grey Rubber Stopper and Light Pink Flip-off Seal Packed in Individual Box (Box of 10's)
Rx
United Biotech Pvt. Ltd.India
HLM Pharmaceutical, Inc.Importer: Triple Tact Import & Export Corp.
DRP-12456-03
Aug 10, 2027
VancolevVancomycin (as Hydrochloride)
500 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Moulded Glass Vial (Box of 1's)
Rx
United Biotech Pvt. Ltd.India
HLM Pharmaceutical, Inc.Importer: Triple Tact Import & Export Corp.
DRP-11780-03
Jul 21, 2027
VancolifeVancomycin (as hydrochloride)
1 g Lyophilized Powder for Injection for I.V. InfusionUSP Type 1.colorless clear glass vial with lyophilized rubber stopper and gray aluminum cap (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd.Korea
Unilab, Inc.
DRP-12496
Aug 26, 2027
VancolifeVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (I.V.)USP Type I clear colorless glass vial with lyophilized rubber stopper and dark blue aluminum cap (Box of 10's)
Rx
BCWorld Pharm. Co., Ltd. (1357)Republic of Korea
UNILAB, Inc.Importer: JLT Pharma Inc.
DRP-9845-02
Jul 15, 2031
Vancolite 1000Vancomycin (as Hydrochloride)
1 g Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Pink Aluminum Flip-Off Seal Cap x 1's + 10 mL Sterile Water for Injection (diluent) in Type I Clear Glass Ampoule (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals, Inc.
DRP-13104
Dec 1, 2027
Vancolite 500Vancomycin (as Hydrochloride)
500mg Powder for Injection (IM/IV)10 mL Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Pink Aluminum Flip-Off Seal Cap x 1's + 10 mL Sterile Water for Injection (diluent) in Clear Glass Ampoule (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals, Inc.
DRP-13105
Dec 1, 2027
VancolonVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (IV)USP Type I Clear Borosilicate Glass Vial (Box of 1's)
Rx
Gulf Pharmaceutical Industries (Julphar)United Arab Emirates
Britton Distributions, Inc.
DR-XY36463
Aug 13, 2029
VancomarcVancomycin (As Hydrochloride)
1g Powder For I.V. Infusion10 mL-Capacity USP Type II Glass Tubular Vial with butyl rubber stopper and flip-off cap (Box 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Marcburg Philippines Inc.
DR-XY48525
Dec 12, 2027
VancomarcVancomycin (as hydrochloride)
500 mg Powder for Injection (IV)10 mL-capacity USP Type II glass rubber stopper, aluminum seal, and blue flip-off cap (Box of 1's
Rx
Reyoung Pharmaceutical Co., LtdChina
Marcburg Philippines Inc.
DR-XY49467
Aug 8, 2030
VancomaxVancomycin Hydrochloride
1 g Powder for I.V. InfusionUSP Type II transparent and colorless tubular vials x 10 mL (Box of 1')
Rx
Reyoung Pharmaceutical Co. Ltd.China
Global Pharmatrade
DR-XY48707
May 15, 2028
VancomaxVancomycin Hydrochloride
500 mg Powder For Injection I.V. Infusion10mL USP Type II Glass, Tubular Vials, Sealed with Butyl Rubber Stopper, Flip-Off Caps, and Adhesive Label
Rx
Reyoung Pharmaceutical Co. Ltd.China
Global Pharmatrade
DR-XY48706
May 15, 2028
VancomedVancomycin Hydrochloride
1 g Powder For Injection (IV)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Sanimed Pharmaceuticals Inc.
DRP-11344
Mar 3, 2027
VancomedVancomycin Hydrochloride
500 mg Powder For Injection (IV)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Sanimed Pharmaceuticals Inc.
DRP-11345
Mar 3, 2027
VancomeedVancomycin
1 g Powder for Injection (I.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-11397-02
Mar 8, 2032
VancomeedVancomycin
500 mg Powder for Injection (I.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's, 10's, and 50's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc.
DRP-11398-01
Mar 8, 2027
VancomyxibVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
BioRx Pharma Labs LLPIndia
BSV Bioscience Phils. Inc.Importer: Ambica International Corporation
DRP-7386-05
Oct 4, 2027
Vanconix 1000Vancomycin Hydrochloride
1 g Powder for Injection (I.V.)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11344-02
Mar 3, 2027
Vanconix 500Vancomycin Hydrochloride
500 mg Powder for Injection (I.V.)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Compharm, Inc.Importer: Sanimed Pharmaceuticals Inc
DRP-11345-03
Mar 3, 2027
Vanconov 1000Vancomycin (as hydrochloride)
1g Powder for Injection (IV Infusion)20 mL Type III Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Blue Aluminum Seal Cap x 1's (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Medinova Pharmaceutical Inc.
DRP-15341
Jun 25, 2029
Vanconov 500Vancomycin (as hydrochloride)
500 mg Powder for Injection (IV Infusion)Glass Vial with 20 mm Flip-Off Seal and 20 mm Grey Butyl Rubber Stopper x 10 mL (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Medinova Pharmaceutical Inc.
DRP-15597
Aug 8, 2029
VancopharVancomycin (as Hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1’s)
Rx
Swiss Parenterals Ltd. (Block B)India
D&G PharmaImporter: Ambica International Corporation
DRP-7386-09
Oct 4, 2027
VancorestVancomycin (as hydrochloride)
500 mg Lyophilized Powder for Injection (IV)Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Lek Pharmaceuticals d.d.Slovenia
Importer: Sandoz Philippines Corporation
DRP-7110
Jan 30, 2029
VANCORYVancomycin (As Hydrochloride)
500 mg Powder For Injection (Iv)10 mL Capacity Type II Tubular Glass Vial with Bromobutyl Rubber Stopper And Blue-Colored Flip-Off Cap (Box of 1’s and 10’s)
Rx
Reyoung Pharmaceutical CoChina
Aglobal Care, Inc.
DRP-11915
Jun 28, 2032
VancosanVancomycin
1 g Powder for Injection (I.V.)10 mL USP Type II colorless glass vial, with gray bromobutyl rubber stopper, aluminum cap, and blue plastic flip-off seal (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Bansan Pharma DistributorImporter: Ambicare Pharmaceuticals Inc.
DRP-11397-01
Mar 8, 2032
Vancosaph-1000Vancomycin (as hydrochloride)
1 g Lyophilized Powder for IV Infusion20 mL-Capacity USP Type I Clear Glass Vial with Grey Bromo Butyl Rubber Stopper and light blue colored Aluminum Flip-Off Seal (Box of l's)
Rx
Kilitch Drugs India Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12798
Oct 7, 2027
Vancosaph-500Vancomycin (as hydrochloride)
500mg Lyophilized Powder for IV Infusion10 mL-Capacity USP Type I Clear Colorless Glass Vial with Grey Bromo Butyl Rubber Stopper and purple colored Aluminum Flip-Off Seal (Box of 1's)
Rx
Kilitch Drugs India Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12799
Oct 7, 2027
Vancosar 1000Vancomycin Hydrochloride
1 g Powder for Injection (I.V.)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11344-01
Mar 3, 2027
Vancosar 500Vancomycin Hydrochloride
500 mg Powder for Injection (I.V.)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11345-01
Mar 3, 2027
Vancosave-1000Vancomycin (as hydrochloride)
1g Powder for Injection (I.V.)20 mL USP Type 1 Clear Glass Vial (Box of 1's)
Rx
Indasi Lifescience Pvt. Ltd.India
Savelink Pharma and Trading Co.Importer: AGlobal Care Inc.
DRP-15297-01
Jun 13, 2029
VancoskyVancomycin (as hydrochloride)
1g Dry Powder for Injection (IV Infusion)20 mL Clear Glass Vial Sealed with Gray Butyl Rubber Stopper and Sky-Blue Flip-Off Seal Cap x 1's (Box of I's)
Rx
Skymap Healthcare Pvt. LtdIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-14583
Oct 18, 2028
Vancotan 1000Vancomycin (as hydrochloride)
1 g Lyophilized Powder for IV InjectionUSP Type I glass vial x 20 mL + 2 USP Type III Flint Glass Ampoule x 10 mL of Water for Injection (Box of 1's)
Rx
Gufic Biosciences Ltd.India
SRS Life Sciences Inc.
DR-XY41546
Sep 6, 2028
Vancotan 500Vancomycin (as hydrochloride)
500 mg Lyophilized Powder for IV Infusion
Rx
Gufic Biosciences Ltd.
SRS Life Sciences Inc.
DRP-9864
Jun 21, 2027
VancotorVancomycin (as Hydrochloride)
1 g Lyophilized Powder for IV Infusion20 mL USP Type I Clear Moulded Glass Vial with Grey Rubber Stopper and Light Pink Flip-off Seal Packed in Individual Box (Box of 10 's)
Rx
United Biotech Pvt. Ltd.India
Altor Pharmaceutical Product DistributionImporter: Triple Tact Import & Export Corp.
DRP-12456-02
Aug 10, 2027
VancotorVancomycin (as Hydrochloride)
500 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Moulded Glass Vial (Box of 1's)
Rx
United Biotech Pvt. Ltd.India
Altor Pharmaceutical Product DistributionImporter: Triple Tact Import & Export Corp.
DRP-11780-02
Jul 21, 2027
VancotrixVancomycin Hydrochloride
1 g Lyophilized Powder for Injection (IV Infusion)10 mL-capacity USP Type I glass vial with grey chlorobutyl rubber stopper, aluminum seal and yellow flip-off cap (Box of 10's)
Rx
Hankook Korus Pharm. Co., Ltd.Korea
Bestco. Pharma International Corporation
DRP-17037
Sep 12, 2030
VancotrixVancomycin Hydrochloride
500 mg Lyophilized Powder for Injection (IV Infusion)10 mL-capacity USP Type I glass vial with grey chlorobutyl rubber stopper, aluminum seal and green flip-off cap (Box of 10's)
Rx
Hankook Korus Pharm. Co., Ltd.Korea
Bestco. Pharma International Corporation
DRP-17038
Sep 12, 2030
VANCOWALLVancomycin (as hydrochloride)
500 mg Powder fo Injection (I.V.)10 mL-net capacity USP Type III clear vial with grey bromo butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
Rx
Swiss Parenterals Ltd. (Block B)India
Rifemedica CorporationImporter: 2MG Incorporated
DRP-16234-01
Jan 3, 2030
VancowellVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Rifemedica CorporationImporter: Ambica International Corporation
DRP-7387-01
Oct 4, 2027
VancowellVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
BioRx Pharma Labs LLPIndia
Rifemedica CorporationImporter: Ambica International Corporation
DRP-7386-04
Oct 4, 2027
VancoxycVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-7387-04
Oct 4, 2027
VancoxycVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
Swiss Parenterals Ltd. (Block B)India
Diafarm Inc.Importer: Ambica International Corporation
DRP-7386-06
Oct 4, 2027
Vancoza-1Vancomycin (as hydrochloride)
1 g Powder for Injection (I.V.)20 mL-capacity Clear Molded Glass Vial with grey butyl rubber stopper and red aluminum flip-off seal (Box of 1's)
Rx
Sanjar Pharma LLPIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-13852
May 2, 2028
Vancoza-500Vancomycin (as hydrochloride)
500 mg Powder for Injection (I.V.)10 mL-capacity Clear Molded Glass Vial with grey butyl rubber stopper and red aluminum flip-off seal (Box of 1's)
Rx
Sanjar Pharma LLPIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-13851
May 2, 2028
VancozenVancomycin Hydrochloride
500 mg Powder for Injection (I.V.)10 mL USP Type II Tubular Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Genzen Pharmaceutical TradingImporter: Sanimed Pharmaceuticals Inc.
DRP-11345-02
Mar 3, 2027
VancynVancomycin (As Hydrochloride)
1 g Powder For Injection (IV)10 mL-capacity USP Type II Tubular glass vial with butyl rubber stopper and flip-off seal (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Phil. Pak Pharma Inc.
DRP-11173
Mar 29, 2027
VancynVancomycin (As Hydrochloride)
500 mg Powder For Injection10 mL-capacity USP Type II Tubular glass vial with butyl rubber stopper and flip-off seal (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Phil. Pak Pharma Inc.
DRP-11172
Mar 29, 2027
Vankar 500Vancomycin (as hydrochloride)
500 mg Lyophilized Powder For Injection (I.V.) Infusion10mL Clear tubular vial with grey bromobutyl rubber stopper and aluminum flip off seal (Box of 1's).
Rx
Sakar Healthcare LimitedIndia
Macropharma Corporation.
DRP-14099
Jun 21, 2028
Vansafe-CPVancomycin (as hydrochloride)
1 g Powder For Injection (I.V.)20 mL USP Type I glass vial with grey-colored rubber stopper and aluminum flip-off seal (Box og 1's)
Rx
VHB Medi Sciences LimitedIndia
Brady Pharma Inc.
DR-XY48758
Jun 1, 2028
Vansafe-CPVancomycin (as hydrochloride)
500 mg Powder for Solution for Intravenous Infusion10 mL-capacity USP Type I glass vial with gray butyl rubber stopper, aluminum seal and blue polypropylene flip-off cap (Box of 1's).
Rx
VHB Medi Sciences LimitedIndia
Brady Pharma Inc.
DR-XY49118
Jun 28, 2029
VantamVancomycin (as hydrochloride)
1 g Powder for IV Infusion20 mL-capacity USP Type III moulded glass vial with gray bromobutyl rubber stopper and blue flip-off seal x 1's + 2 Sterile Water for Injection (diluent) in USP Type I Clear glass ampoule x 10 mL in a box.
Rx
Shree Anand Life Sciences, Ltd.India
Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc.
DRP-14780-01
Jan 4, 2029
Varcelan-500Vancomycin (As Hydrochloride)
500 mg Powder for Injection (IV)USP Type III Clear Glass Vial in monocarton with blue flip-off seal (Box of 1's and 10's)
Rx
Lyka Labs, Ltd.India
Arvincare Pharma Inc.
DRP-4638
Aug 28, 2030
VaxcicinVancomycin (as Hydrochloride)
1 g Powder For Injection10 mL-capacity USP Type II Tubular glass vial with butyl rubber stopper and flip off seal (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Philgen Pharmaceuticals Inc.
DRP-15196
May 27, 2029
VaxcicinVancomycin (as Hydrochloride)
500 mg Powder For Injection10 mL-capacity USP Type II Tubular glass vial with butyl rubber stopper and flip off seal (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Philgen Pharmaceuticals Inc.
DRP-15197
May 27, 2029
VencusinVancomycin (as hydrochloride)
1 g Powder for Injection (I.V. Infusion)20 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
Swiss Parenterals Ltd.India
Sonchel Pharma DistributorsImporter: Ambica International Corporation
DRP-7387-02
Oct 4, 2027
VencusinVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V. Infusion)10 mL capacity USP Type I Clear and Colorless Glass Vial (Box of 1 Vial)
Rx
BioRx Pharma Labs LLPIndia
Sonchel Pharma DistributorsImporter: Ambica International Corporation
DRP-7386-02
Oct 4, 2027
VycocinVancomycin (as hydrochloride)
500 mg Powder for Injection (I.V.)USP Type I clear glass vial with blue plastic flip-off cap (Box of 10's)
Rx
Union Korea Pharm Co., Ltd.Republic of Korea
Ellebasy Medicale TradingImporter: H & B Pharma International Inc.
DRP-5822-03
Aug 27, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Vancomycin Hydrochloride for Injection is a sterile white, almost white to tan to brown, spray-dried powder in single-dose vials each containing vancomycin hydrochloride equivalent to 500 mg, 750 mg, 1 gram, 1.25 grams or 1.5 grams vancomycin base. Vancomycin Hydrochloride for Injection is a sterile spray-dried powder for injection in single-dose vials containing vancomycin hydrochloride equivalent to 500 mg, 750 mg, 1 gram, 1.25 grams or 1.5 grams of vancomycin base (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Nephrotoxicity: Systemic vancomycin exposure may result in acute kidney injury (AKI) including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. Monitor serum vancomycin concentrations and renal function in patients receiving Vancomycin Hydrochloride for Injection intravenously. Monitor renal function in patients over 65 years of age receiving Vancomycin Hydrochloride for Injection orally. (5.1)
  • Ototoxicity: Ototoxicity has occurred in patients administered vancomycin intravenously or orally. Monitor for signs and symptoms of ototoxicity during oral or intravenous therapy. Assessment of auditory function may be appropriate in some instances. (5.2)
  • Severe Dermatologic Reactions: Discontinue Vancomycin Hydrochloride for Injection at the first appearance of skin rashes, mucosal lesions, or blisters (5.3). Neutropenia: This has been reported in patients administered vancomycin intravenously or orally. Periodically monitor leukocyte count. (5.4)
  • Infusion Reactions: Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular, chest pain and vancomycin infusion reaction which manifests as pruritus and erythema that involves the face, neck and upper torso may occur with rapid intravenous administration. To reduce the risk of infusion reactions, administer Vancomycin Hydrochloride for Injection in …
5.1 Nephrotoxicity Vancomycin Hydrochloride

5.1 Nephrotoxicity Vancomycin Hydrochloride for Injection administered intravenously or orally can result in acute kidney injury (AKI), including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. AKI is manifested by increasing blood urea nitrogen (BUN) and serum creatinine (Cr).

The risk of AKI increases with higher vancomycin serum levels, prolonged exposure, concomitant administration of other nephrotoxic drugs, concomitant administration of piperacillin-tazobactam [see Drug Interactions (7.2)], volume depletion, pre-existing renal impairment and in critically ill patients and patients with co-morbid conditions that predispose to renal impairment. Monitor serum vancomycin concentrations and renal function in all patients receiving Vancomycin Hydrochloride for Injection intravenously.

Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatine increased) has occurred following oral vancomycin hydrochloride capsule therapy in randomized controlled clinical studies and can occur either during or after completion of therapy. The risk of nephrotoxicity is increased in patients >65 years of age [see Adverse Reactions (6.1) and Use in Specific Populations (8.5)].

In patients over 65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with oral Vancomycin Hydrochloride for Injection therapy to detect potential vancomycin induced nephrotoxicity. More frequent monitoring is recommended in patients with comorbidities that predispose to impairment in renal function or are concomitantly receiving other nephrotoxic drugs, in critically ill patients, in patients with changing renal function, and in patients requiring higher therapeutic vancomycin levels.

If acute kidney injury occurs, discontinue Vancomycin Hydrochloride for Injection or reduce the dose.

5.2 Ototoxicity

5.2 Ototoxicity Ototoxicity has occurred in patients administered vancomycin intravenously or orally. It may be transient or permanent. Ototoxicity manifests as tinnitus, hearing loss, dizziness or vertigo. The risk is higher in older patients, patients who are receiving higher doses, who have an underlying hearing loss, who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside or who have underlying renal impairment.

Monitor for signs and symptoms of ototoxicity during oral or intravenous therapy with Vancomycin Hydrochloride for Injection. Discontinue Vancomycin Hydrochloride for Injection if ototoxicity occurs. Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity.

5.3 Severe Dermatologic Reactions

5.3 Severe Dermatologic Reactions Severe dermatologic reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported in association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters.

Discontinue Vancomycin Hydrochloride for Injection at the first appearance of signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD.

5.4 Neutropenia

5.4 Neutropenia Reversible neutropenia has been reported in patients administered vancomycin intravenously or orally. Patients who will undergo prolonged therapy with Vancomycin Hydrochloride for Injection or those who are receiving concomitant drugs which may cause neutropenia should have periodic monitoring of the leukocyte count.

5.5 Infusion Reactions

5.5 Infusion Reactions Hypotension, including shock and cardiac arrest, wheezing, dyspnea, urticaria, muscular and chest pain may occur with rapid Vancomycin Hydrochloride for Injection intravenous administration. The reactions may be more severe in younger patients, particularly children, and in patients receiving concomitant muscle relaxant anesthetics.

Rapid intravenous administration of Vancomycin Hydrochloride for Injection may also be associated with vancomycin infusion reaction, which manifests as pruritus and erythema that involves the face, neck and upper torso. Infusion-related adverse reactions are related to both the concentration and the rate of administration of Vancomycin Hydrochloride for Injection.

Infusion-related adverse reactions may occur, however, at any rate or concentration. Administer Vancomycin Hydrochloride for Injection in a diluted solution over a period of 60 minutes or greater to reduce the risk of infusion-related adverse reactions. In selected patients in need of fluid restriction, a concentration up to 10 mg/mL may be used; use of such higher concentrations may increase the risk of infusion-related adverse reactions [see Nonclinical Toxicology (13.2)].

Administer prior to intravenous anesthetic agents when feasible. Stop the infusion if a reaction occurs.

5.6 Phlebitis and Adverse Reactions with Unapproved Routes of Administration

5.6 Phlebitis and Adverse Reactions with Unapproved Routes of Administration Inflammation at the site of injection of vancomycin has been reported. Vancomycin is irritating to tissue and must be given by a secure intravenous route of administration to reduce the risk of local irritation and phlebitis. Thrombophlebitis may occur, the frequency and severity of which can be minimized by slow infusion of the drug and by rotation of venous access sites.

Administration of Vancomycin Hydrochloride for Injection by intramuscular (IM), intraperitoneal, intrathecal intraventricular, or intravitreal routes has not been approved and is not recommended. The safety and efficacy of vancomycin administered by these routes of administration have not been established by adequate and well controlled trials.

Pain, tenderness, and necrosis occur with IM injection of vancomycin or with inadvertent extravasation. Intraperitoneal administration during continuous ambulatory peritoneal dialysis (CAPD) can result in chemical peritonitis. Manifestations range from cloudy dialysate alone to a cloudy dialysate accompanied by variable degrees of abdominal pain and fever.

This syndrome appears to be resolved after discontinuation of intraperitoneal vancomycin. About 60% of an intraperitoneal dose of vancomycin administered during peritoneal dialysis is absorbed systemically in 6 hours. Serum concentrations of about 10 mcg/mL are achieved by intraperitoneal injection of 30 mg/kg of vancomycin.

However, the safety and efficacy of the intraperitoneal use of vancomycin has not been established in adequate and well-controlled trials.

5.7 Clostridioides difficile

5.7 Clostridioides difficile -Associated Diarrhea (CDAD) Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including with intravenous administration of vancomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Clinically significant serum concentrations of vancomycin have been reported in some patients being treated for active C. difficile -induced pseudomembranous colitis after multiple oral doses of vancomycin [see Warnings and Precautions (5.10)]. Prolonged use of Vancomycin Hydrochloride for Injection may result in the overgrowth of non-susceptible microorganisms.

Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. There have been reports of pseudomembranous colitis due to C. difficile developing in patients who received intravenous vancomycin.

5.8 Hemorrhagic Occlusive Retinal Vasculitis (HORV)

5.8 Hemorrhagic Occlusive Retinal Vasculitis (HORV) Hemorrhagic occlusive retinal vasculitis, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established by adequate and well-controlled trials.

Vancomycin Hydrochloride for Injection (intravenously and orally administered) is not indicated for the prophylaxis of endophthalmitis.

5.9 Development of Drug-Resistant Bacteria Prescribing

5.9 Development of Drug-Resistant Bacteria Prescribing Vancomycin Hydrochloride for Injection (intravenously and orally administered) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

5.10 Potential for Systemic

5.10 Potential for Systemic Absorption after Oral Administration Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of oral vancomycin for active C. difficile -associated diarrhea. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of vancomycin.

These patients may be at risk for the development of adverse reactions associated with higher doses of oral vancomycin; therefore, monitoring of serum concentrations of vancomycin may be appropriate in some instances, e.g., in patients with renal insufficiency and/or colitis or in those receiving concomitant therapy with an aminoglycoside antibacterial drug.

Drug interactions

Drug or classSeverityEffectWhat to do
Piperacillin-tazobactamAdjust or monitorMore acute kidney injury than vancomycin alone.Monitor kidney function.
Other nephrotoxic or ototoxic drugs (concurrent or sequential, systemic or topical)Adjust or monitorAdditive kidney and ear toxicity.Monitor kidney function more often.
Anesthetic agentsMinorErythema and histamine-like flushing.Infuse vancomycin before anesthesia induction as the label advises.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • Anesthetic Agents: Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing. (2.1, 7.1)
  • Piperacillin/Tazobactam: Increased incidence of acute kidney injury in patients administered concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients (7.2)
7.1 Anesthetic Agents

7.1 Anesthetic Agents Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing [see Warnings and Precautions (5.5) and Use in Specific Populations (8.4)].

7.2 Piperacillin-Tazobactam

7.2 Piperacillin-Tazobactam Studies have detected an increased incidence of acute kidney injury in patients administered concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients receiving concomitant piperacillin/tazobactam and Vancomycin Hydrochloride for Injection.

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

7.3 Ototoxic

7.3 Ototoxic and/or Nephrotoxic Drugs Concurrent and/or sequential systemic or topical use of other potentially, neurotoxic and/or nephrotoxic drugs requires more frequent monitoring of renal function.

Adverse reactions

Common

  • Label lists as common (IV and oral): acute kidney injury, hearing loss, neutropenia, anaphylaxis, vancomycin infusion reaction
  • Oral use (more than 10%): nausea, abdominal pain, hypokalemia

Serious

  • Infusion reactions with rapid infusion (hypotension, shock, cardiac arrest)
  • Nephrotoxicity (acute kidney injury)
  • Ototoxicity
  • Severe dermatologic reactions (TEN, SJS, DRESS)
  • Clostridioides difficile-associated diarrhea
  • Hemorrhagic occlusive retinal vasculitis (intracameral/intravitreal use)
  • Reversible neutropenia
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Nephrotoxicity [see Warnings and Precautions (5.1)] Ototoxicity [see Warnings and Precautions (5.2)] Severe Dermatologic Reactions [see Warnings and Precautions (5.3)] Neutropenia [see Warnings and Precautions (5.4)] Infusion Reactions [see Warnings and Precautions (5.5)] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.7)] The common adverse reactions following intravenously, and orally administered vancomycin were acute kidney injury, hearing loss, neutropenia, anaphylaxis, vancomycin infusion reaction. (6.1)
  • The most common adverse reactions of orally administered vancomycin (> 10%) were nausea, abdominal pain, and hypokalemia (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Avenacy at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Patients Receiving Intravenously and Orally Administered Vancomycin The following adverse reactions associated with the use of intravenously and orally administered vancomycin were identified in clinical trials: Renal and urinary disorders: Acute kidney injury and interstitial nephritis [see Warnings and Precautions (5.1)] Ear and labyrinth disorders: Tinnitus, hearing loss, vertigo [see Warnings and Precautions (5.2)] Skin and subcutaneous tissue disorders: Erythema (especially of the face, neck and upper torso) and pruritus which are manifestations of rashes including exfoliative dermatitis, toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), Linear IgA bullous dermatosis (LABD) [see Warnings and Precautions (5.3)].

Blood and lymphatic system disorders: Agranulocytosis, neutropenia, pancytopenia, leukopenia, thrombocytopenia, eosinophilia [see Warnings and Precautions (5.4)] Immune system disorders: Hypersensitivity reactions including anaphylaxis and vancomycin infusion reaction [see Warnings and Precautions (5.5)] General disorders and administration site conditions: General discomfort, fever, chills, phlebitis, injection site irritation, injection site pain and necrosis following intramuscular injection, chemical peritonitis following intraperitoneal administration. Vancomycin Hydrochloride for Injection is not approved for intramuscular and intraperitoneal administration [see Warnings and Precautions (5.6)] Gastrointestinal disorders: Pseudomembranous colitis [see Warnings and Precautions (5.7)] Cardiac disorders: Cardiac arrest, chest pain Laboratory abnormalities: Elevated blood urea nitrogen, elevated serum creatinine Musculoskeletal and connective tissue disorders: Muscle pain Nervous system disorders: Dizziness Respiratory, thoracic and mediastinal disorders: Wheezing, dyspnea Vascular disorders: Hypotension, shock, vasculitis Adverse Reactions in Patients Receiving Oral Administration of Vancomycin Hydrochloride Capsules The data described below reflect exposure to vancomycin hydrochloride capsules in 260 adult subjects in two Phase 3 clinical trials for the treatment of diarrhea associated with C. difficile.

In both trials, subjects received vancomycin hydrochloride capsules 125 mg orally four times daily. The mean duration of treatment was 9.4 days. The median age of patients was 67, ranging between 19 and 96 years of age. Patients were predominantly Caucasian (93%) and 52% were male. Adverse reactions occurring in ≥5% of vancomycin hydrochloride capsules-treated subjects are shown in Table 2.

The most common adverse reactions associated with vancomycin hydrochloride capsules (≥10%) were nausea, abdominal pain, and hypokalemia. Table 2: Common (≥5%) Adverse Reactions a for Vancomycin Hydrochloride Capsules Reported in Clinical Trials for Treatment of Diarrhea Associated with C. difficile a Adverse reaction rates were derived from the incidence of treatment-emergent adverse events.

System/Organ Class Adverse Reaction Vancomycin Hydrochloride Capsule % (N=260) Gastrointestinal disorders Nausea Abdominal pain Vomiting Diarrhea Flatulence 17 15 9 9 8 General disorders and administration site conditions Pyrexia Edema peripheral Fatigue 9 6 5 Infections and infestations Urinary tract infection 8 Metabolism and nutrition disorders Hypokalemia 13 Musculoskeletal and connective tissue disorders Back pain 6 Nervous system disorders Headache 7 Nephrotoxicity (e.g., reports of renal failure, renal impairment, blood creatinine increased) occurred in 5% of subjects treated with vancomycin hydrochloride capsules. Nephrotoxicity following vancomycin hydrochloride capsules typically first occurred within one week after completion of treatment (median day of onset was Day 16).

Nephrotoxicity following vancomycin hydrochloride capsules occurred in 6% of subjects >65 years of age and 3% of subjects ≤65 years of age. The incidences of hypokalemia, urinary tract infection, peripheral edema, insomnia, constipation, anemia, depression, vomiting, and hypotension were higher among subjects >65 years of age than in subjects ≤65 years of age.

Discontinuation of study drug due to adverse events occurred in 7% of subjects treated with vancomycin hydrochloride capsules. The most common adverse events leading to discontinuation of vancomycin hydrochloride capsules were C. difficile colitis (<1%), nausea (<1%), and vomiting (<1%).

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postmarketing use of vancomycin (administered orally and intravenously). Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and Subcutaneous Tissue Disorders: Drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) [see Warnings and Precautions (5.3)]. Ototoxicity: Cases of hearing loss associated with intravenously administered vancomycin have been reported. Most of these patients had kidney dysfunction or a preexisting hearing loss or were receiving concomitant treatment with an ototoxic drug [see Warnings and Precautions (5.2)].

Vertigo, dizziness, and tinnitus have been reported. Hematopoietic: Reversible neutropenia, usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported for several dozen patients. Neutropenia appears to be promptly reversible when vancomycin is discontinued.

Thrombocytopenia has been reported. Miscellaneous: Patients have been reported to have had anaphylaxis, drug fever, chills, nausea, eosinophilia, and cases of vasculitis in association with the administration of vancomycin. A condition has been reported with oral vancomycin that is similar to the intravenous vancomycin-induced syndrome with symptoms consistent with anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“vancomycin infusion reaction”), pain and muscle spasm of the chest and back [see Warnings and Precautions (5.5)].

These reactions usually resolve within 20 minutes but may persist for several hours.

Adverse reaction frequency tables (US label) US FDA label
Table 2: Common (≥5%) Adverse Reactionsa for Vancomycin Hydrochloride Capsules Reported in Clinical Trials for Treatment of Diarrhea Associated with C. difficile
aAdverse reaction rates were derived from the incidence of treatment-emergent adverse events.
System/Organ ClassAdverse ReactionVancomycin Hydrochloride Capsule % (N=260)
Gastrointestinal disordersNausea Abdominal pain Vomiting Diarrhea Flatulence 17 15 9 9 8
General disorders and administration site conditionsPyrexia Edema peripheral Fatigue 9 6 5
Infections and infestationsUrinary tract infection 8
Metabolism and nutrition disordersHypokalemia 13
Musculoskeletal and connective tissue disordersBack pain 6
Nervous system disordersHeadache 7

Monitoring parameters

  • Serum concentrations (AUC-guided, target 400–600 mg·h/L, per consensus; trough per label); pre-dialysis levels at least weekly on hemodialysis; serum creatinine; nephrotoxicity risk rises with other nephrotoxins. Kidney
  • Serum vancomycin concentrations
  • Kidney function
  • Auditory function in at-risk patients
  • Blood counts with prolonged therapy
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no available data on vancomycin use in pregnant women to inform a drug associated risk of major birth defects or miscarriage. Available published data on vancomycin use in pregnancy during the second and third trimesters have not shown an association with adverse pregnancy related outcomes (see Data).

Vancomycin did not show adverse developmental effects when administered intravenously to pregnant rats and rabbits during organogenesis at doses less than or equal to the recommended maximum human dose (see Data). Systemic absorption of vancomycin is low following oral administration of vancomycin hydrochloride capsules; however, absorption may vary depending on various factors [see Clinical Pharmacology (12.3)].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Human Data A published study evaluated hearing loss and nephrotoxicity in infants of 10 pregnant intravenous drug users treated with intravenously administered vancomycin for suspected or documented methicillin-resistant Staphylococcus-aureus (MRSA) infections in the second or third trimester. The comparison groups were 10 non-intravenous drug-dependent patients who received no treatment, and 10 untreated intravenous drug-dependent patients who served as substance abuse controls.

No infant in the vancomycin exposed group had abnormal sensorineural hearing at 3 months of age or nephrotoxicity. A published prospective study assessed outcomes in 55 pregnant women with a positive Group B streptococcus (GBS) culture and a high-risk penicillin allergy with resistance to clindamycin or unknown sensitivity who were administered vancomycin intravenously at the time of delivery.

Vancomycin dosing ranged from the standard 1 g intravenously every 12 hours to 20 mg/kg intravenous every 8 hours (maximum individual dose 2 g). No major adverse reactions were recorded either in the mothers or their newborns. None of the newborns had sensorineural hearing loss. Neonatal renal function was not examined, but all of the newborns were discharged in good condition.

Animal Data Vancomycin did not cause fetal malformations when administered during organogenesis to pregnant rats (gestation days 6 to 15) and rabbits (gestation days 6 to 18) at the equivalent recommended maximum human dose (based on body surface area comparisons) of 200 mg/kg/day IV to rats or 120 mg/kg/day IV to rabbits 1. No effects on fetal weight or development were seen in rats at the highest dose tested or in rabbits given 80 mg/kg/day (approximately 1 and 0.8 times the recommended maximum human dose based on body surface area, respectively).

Maternal toxicity was observed in rats (at doses 120 mg/kg and above) and rabbits (at 80 mg/kg and above). There were no oral embryo-fetal toxicity studies conducted in animals with this Vancomycin Injection product.

Mechanism of action

12.1 Mechanism of Action Vancomycin is an antibacterial drug [see Microbiology (12.4)].

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The pharmacodynamics of vancomycin is unknown.

Pharmacokinetics

Key PK parameters

Half-life4 to 6 hours (normal kidney function)
Half-life in kidney failure (ESKD) kidneyAbout 7.5 days in anephric patients (label)
Volume of distribution0.3 to 0.43 L/kg (label)
Protein bindingAbout 55%
Metabolism (CYP, transporters)No apparent metabolism
Active metabolitesNone
Renal excretion kidneyAbout 75% in urine in 24 hours (glomerular filtration)
Dialyzability kidneyYes with high-flux HD: substantial removal each session (median 31% per session high-flux vs 17% low-flux in Petejova 2012); the label's 'poorly removed by dialysis' reflects older low-flux membranes. Hemofiltration and polysulfone hemoperfusion also increase clearance (label).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

No blood concentrations were detected, and urinary recovery did not exceed 0.76%.

It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly [see Use in Specific Populations ( 8.5 )] .

Elimination Mean plasma clearance is about 0.058 L/kg/h, and mean renal clearance is about 0.048 L/kg/h.

The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function.

In anephric patients, the mean elimination half-life is 7.5 days.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics General Pharmacokinetics In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion of infusion, mean plasma concentrations of approximately 23 mcg/mL 2 hours after infusion, and mean plasma concentrations of approximately 8 mcg/mL 11 hours after the end of the infusion. Multiple dosing of 500 mg infused over 30 minutes produces mean plasma concentrations of about 49 mcg/mL at the completion of infusion, mean plasma concentrations of about 19 mcg/mL 2 hours after infusion, and mean plasma concentrations of about 10 mcg/mL 6 hours after infusion.

The plasma concentrations during multiple dosing are like those after a single dose. Absorption Vancomycin is poorly absorbed after oral administration. During multiple dosing of 250 mg every 8 hours for 7 doses, fecal concentrations of vancomycin in volunteers exceeded 100 mg/kg in the majority of samples. No blood concentrations were detected, and urinary recovery did not exceed 0.76%.

In anephric subjects with no inflammatory bowel disease who received vancomycin oral solution 2 g for 16 days, blood concentrations of vancomycin were less than or equal to 0.66 mcg/mL in 2 of 5 subjects. No measurable blood concentrations were attained in the other 3 subjects. Following doses of 2 g daily, concentrations of drug were >3100 mg/kg in the feces and <1 mcg/mL in the serum of subjects with normal renal function who had C. difficile -associated diarrhea.

After multiple-dose oral administration of vancomycin, measurable serum concentrations may occur in patients with active C. difficile -associated diarrhea, and, in the presence of renal impairment, the possibility of accumulation exists. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly [see Use in Specific Populations (8.5)].

Distribution The volume of distribution ranges from 0.3 to 0.43 L/kg after intravenous administration. Vancomycin is approximately 55% serum protein bound as measured by ultrafiltration at vancomycin serum concentrations of 10 to 100 mcg/mL. After intravenous administration of vancomycin, inhibitory concentrations are present in pleural, pericardial, ascitic, and synovial fluids; in urine; in peritoneal dialysis fluid; and in atrial appendage tissue.

Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs. Elimination Mean plasma clearance is about 0.058 L/kg/h, and mean renal clearance is about 0.048 L/kg/h. The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function.

In anephric patients, the mean elimination half-life is 7.5 days. Total body and renal clearance of vancomycin may be reduced in the elderly. Metabolism There is no apparent metabolism of vancomycin. Excretion In the first 24 hours after intravenous administration, about 75% of an administered dose of vancomycin is excreted in urine by glomerular filtration.

Renal impairment slows excretion of vancomycin.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Vancomycin 1 g Vial₱149.24–₱2,302.00Reference ₱313.20per vialDPRI procurement range
Vancomycin 500 mg Vial₱100.00–₱995.00Reference ₱137.22per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Vancomycin (as hydrochloride)
PNF listingInj.: 500 mg and 1 g vial (IV)Restrictions: Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Vancomycin Hydrochloride · Avenacy, LLC [US FDA-approved label, version 1, July 31, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c757e65b-ca6f-4c00-afe2-025962b43d31
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Avenacy, LLC. (2026). Vancomycin hydrochloride for injection (vancomycin hydrochloride; single-dose vials) [Prescribing information; US FDA-approved label, NDA210274, set ID c757e65b-ca6f-4c00-afe2-025962b43d31, version effective July 31, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c757e65b-ca6f-4c00-afe2-025962b43d31
  6. Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K. A., Maples, H. D., & Lomaestro, B. M. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 77(11), 835–864. https://doi.org/10.1093/ajhp/zxaa036
  7. Rybak, M. J., Le, J., Lodise, T., Levine, D., Bradley, J., Liu, C., Mueller, B., Pai, M., Wong-Beringer, A., Rotschafer, J. C., Rodvold, K., Maples, H. D., & Lomaestro, B. M. (2020). Executive summary: Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Journal of the Pediatric Infectious Diseases Society, 9(3), 281–284. https://doi.org/10.1093/jpids/piaa057
  8. Petejova, N., Martinek, A., Zahalkova, J., Duricova, J., Brozmanova, H., Urbanek, K., Grundmann, M., & Kacirova, I. (2012). Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 156(4), 342–347. https://doi.org/10.5507/bp.2012.002
  9. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  10. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
  11. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .